An open-label multiple dose study to evaluate the pharmacokinetics, safety and tolerability of CP-690,550 in pediatric patients from 2 to less than 18 years of age with Juvenile Idiopathic Arthritis (JIA)
Read time: 1 mins
Last updated:17th May 2012
To characterize the PK and safety of CP 690,550 following multiple oral doses in pediatric patients (from 2 to less than 18 years) with active JIA.
|Study start date||2012-05-17|